Clinical trial
A German, Nationwide, Prospective, Observational, Multicenter Study in Patients With First-line Nivolumab Plus Ipilimumab Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
NCT04794010 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A German, Nationwide, Prospective, Observational, Multicenter Study in Patients With First-line Nivolumab Plus Ipilimumab Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- December 22, 2020
- Completion date
- December 22, 2027
- Enrollment
- 825 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.